chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease with (acute) exacerbation
Conditions
Interventions
Intervention 1: Intervention group:Daily use of empagliflozin 10 mg orally manufactured by an Iranian pharmaceutical company for a maximum of 3 months after discharge. Intervention 2: Control group: I
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: age more than 40 years Having chronic obstructive pulmonary disease based on history, imaging and spirometry by a lung specialist
Exclusion criteria
Exclusion criteria: Diabetic patients Kidney failure, GFR 5.2 Liver dysfunction (AST or ALT more than three times the upper limit of normal and biliary cirrhosis and cholestasis) Active malignancy Patient undergoing chemotherapy or immunotherapy Pregnancy and breastfeeding EF<50% History of cardiovascular diseases including more than mild mitral valve insufficiency, more than mild aortic valve insufficiency Left ventricular diastolic failure more than mild, any valvular stenosis in echo and the presence of other causes of right ventricular failureHistory of PHTN such as hypothyroid and hyperthyroid and connective tissue diseases and blood diseases such as thalassemia anemic, tuberculosis, splenectomy and HIV Patients who were hospitalized in the intensive care unit or underwent intubation before the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of acute attacks of COPD during three months after the intervention by empagliflosine group and control group. Timepoint: During three months from the beginning of the study to the end of the study. Method of measurement: visit,history,checklist.;Investigation and comparison of severity of acute attacks of COPD during three months after the intervention by empagliflosine group and control group. Timepoint: During three months from the beginning of the study to the end of the study. Method of measurement: visit,history,checklist.;Investigating and comparing the mortality rate of COPD patients within three months after the intervention, separately from the empagliflosine group and the control group. Timepoint: During three months from the beginning of the study to the end of the study. Method of measurement: visit,history,checklist.;Investigation and comparison of changes in echocardiographic criteria and RV function in non-diabetic COPD patients during three months after the intervention by groupempagliflosine and control group. Timepoint: The beginning of the study and 3 months after that. Method of measurement: echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaman Keshvari Asl
Shahid Beheshti University of Medical Sciences
Outcome results
None listed